Genetic predisposition in nonalcoholic fatty liver disease
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2017;23(1):1-12.   Published online 2017 Mar 9     DOI: https://doi.org/10.3350/cmh.2016.0109
Citations to this article as recorded by Crossref logo
Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Meegun Hong, Dae Hee Han, Jitaek Hong, Dong Joon Kim, Ki Tae Suk
Probiotics and Antimicrobial Proteins.2019; 11(2): 335.     CrossRef
Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach
A. Feldman, S.K. Eder, T.K. Felder, B. Paulweber, S. Zandanell, L. Stechemesser, M. Schranz, G. Strebinger, U. Huber-Schönauer, D. Niederseer, W. Patsch, D. Weghuber, J. Tevini, C. Datz, E. Aigner
Diabetes & Metabolism.2019; 45(2): 132.     CrossRef
Molecular pathways of nonalcoholic fatty liver disease development and progression
Fernando Bessone, María Valeria Razori, Marcelo G. Roma
Cellular and Molecular Life Sciences.2019; 76(1): 99.     CrossRef
Genetics Meets Therapy? Exome-wide Association Study Reveals a Loss-of-Function Variant in 17-Beta-Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression
Silvia Sookoian, Marco Arrese, Carlos J. Pirola, Kathleen E. Corey, Harmeet Malhi
Hepatology.2019; 69(2): 907.     CrossRef
Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
Hsu-Wen Chao, Shi-Wei Chao, Heng Lin, Hui-Chen Ku, Ching-Feng Cheng
International Journal of Molecular Sciences.2019; 20(2): 298.     CrossRef
A Multifaceted Approach regarding the Association of the DsbA-L Gene with the Risk of Obesity-related Diseases Based on Clinical Pharmacogenetics
Kentaro Oniki, Junji Saruwatari
YAKUGAKU ZASSHI.2019; 139(1): 53.     CrossRef
Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
Carlos J. Pirola, Martin Garaycoechea, Diego Flichman, Marco Arrese, Julio San Martino, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian
Journal of Lipid Research.2019; 60(1): 176.     CrossRef
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease
Ki Tae Suk, Dong Joon Kim
Expert Review of Gastroenterology & Hepatology.2019; 13(3): 193.     CrossRef
An integrative systems genetic analysis of mammalian lipid metabolism
Benjamin L. Parker, Anna C. Calkin, Marcus M. Seldin, Michael F. Keating, Elizabeth J. Tarling, Pengyi Yang, Sarah C. Moody, Yingying Liu, Eser J. Zerenturk, Elise J. Needham, Matthew L. Miller, Bethan L. Clifford, Pauline Morand, Matthew J. Watt, Ruth C.
Nature.2019; 567(7747): 187.     CrossRef
Obesity genetics and cardiometabolic health: Potential for risk prediction
Dharambir K. Sanghera, Cynthia Bejar, Sonali Sharma, Rajeev Gupta, Piers R. Blackett
Diabetes, Obesity and Metabolism.2019; 21(5): 1088.     CrossRef
Combined effects of ambient particulate matter exposure and a high-fat diet on oxidative stress and steatohepatitis in mice
Shibin Ding, Chunyan Yuan, Bingjie Si, Mengruo Wang, Shuyan Da, Lanxin Bai, Weidong Wu, Qinghua Sun
PLOS ONE.2019; 14(3): e0214680.     CrossRef
Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
S. Sookoian, C. J. Pirola
Alimentary Pharmacology & Therapeutics.2018; 47(1): 16.     CrossRef
Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents
Oyekoya T. Ayonrinde, Leon A. Adams, Trevor A. Mori, Lawrence J. Beilin, Nicholas de Klerk, Craig E. Pennell, Scott White, John K Olynyk
Hepatology.2018; 67(1): 108.     CrossRef
Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
Lindsey S Treviño, Tiffany A Katz
Endocrinology.2018; 159(1): 20.     CrossRef
Lean NAFLD: A not so benign condition?
Lisa B. VanWagner, Matthew J. Armstrong
Hepatology Communications.2018; 2(1): 5.     CrossRef
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Julia Wattacheril, Danny Issa, Arun Sanyal
Annual Review of Pharmacology and Toxicology.2018; 58(1): 649.     CrossRef
Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy
Alessia Di Costanzo, Francesca Belardinilli, Diego Bailetti, Marialuisa Sponziello, Laura D’Erasmo, Licia Polimeni, Francesco Baratta, Daniele Pastori, Fabrizio Ceci, Anna Montali, Gabriella Girelli, Bruna De Masi, Antonio Angeloni, Giuseppe Giannini, Mar
Scientific Reports.2018;[Epub]     CrossRef
Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
Umberto Vespasiani-Gentilucci, Chiara Dell’Unto, Antonio De Vincentis, Andrea Baiocchini, Marco Delle Monache, Roberto Cecere, Adriano Maria Pellicelli, Valerio Giannelli, Simone Carotti, Giovanni Galati, Paolo Gallo, Francesco Valentini, Franca Del Nonno
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica
Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
Gastroenterología y Hepatología.2018; 41(5): 328.     CrossRef
NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
Subada Soti, Kathleen E. Corey, Jordan E. Lake, Kristine M. Erlandson
Current HIV/AIDS Reports.2018; 15(3): 212.     CrossRef
Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
Carlos J Pirola, Silvia Sookoian
World Journal of Gastroenterology.2018; 24(15): 1601.     CrossRef
The gut–liver axis and the intersection with the microbiome
Anupriya Tripathi, Justine Debelius, David A. Brenner, Michael Karin, Rohit Loomba, Bernd Schnabl, Rob Knight
Nature Reviews Gastroenterology & Hepatology.2018; 15(7): 397.     CrossRef
Nonalcoholic Steatohepatitis
Michael H. Schild, Cynthia D. Guy
Surgical Pathology Clinics.2018; 11(2): 267.     CrossRef
Dietary carbohydrates and fatty liver disease
Sally Chiu, Kathleen Mulligan, Jean-Marc Schwarz
Current Opinion in Clinical Nutrition and Metabolic Care.2018; 21(4): 277.     CrossRef
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
Gastroenterología y Hepatología (English Edition).2018; 41(5): 328.     CrossRef
Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126
Robin Mesnage, Martina Biserni, Sucharitha Balu, Clément Frainay, Nathalie Poupin, Fabien Jourdan, Eva Wozniak, Theodoros Xenakis, Charles A. Mein, Michael N. Antoniou
Archives of Toxicology.2018; 92(8): 2533.     CrossRef
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella, Arun J. Sanyal
Nature Medicine.2018; 24(7): 908.     CrossRef
The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)
Amanda Hanson, Danielle Wilhelmsen, Johanna DiStefano
Non-Coding RNA.2018; 4(3): 18.     CrossRef
Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis
Brett R Loman, Diego Hernández-Saavedra, Ruopeng An, R Scott Rector
Nutrition Reviews.2018; 76(11): 822.     CrossRef
Science, serendipity, and the single degree
Helen H. Hobbs
Journal of Clinical Investigation.2018; 128(10): 4218.     CrossRef
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics
Min Seok Cho, Sang Yeol Kim, Ki Tae Suk, Byung-Yong Kim
Journal of Microbiology.2018; 56(12): 855.     CrossRef
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clinical and Molecular Hepatology.2018;[Epub]     CrossRef
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
Umberto Vespasiani-Gentilucci, Paolo Gallo, Chiara Dell’Unto, Mara Volpentesta, Raffaele Antonelli-Incalzi, Antonio Picardi
World Journal of Gastroenterology.2018; 24(43): 4835.     CrossRef
Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
Silvia Sookoian, Carlos J. Pirola
Annals of Hepatology.2018; 17(2): 182.     CrossRef
Pediatric Non-Alcoholic Fatty Liver Disease
Haley Bush, Pegah Golabi, Zobair M. Younossi
Children.2017; 4(6): 48.     CrossRef
A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
Paola Dongiovanni, Luca Valenti
International Journal of Molecular Sciences.2017; 18(7): 1534.     CrossRef
Hígado graso no alcohólico: una pandemia poco conocida
Salvador Augustin, Isabel Graupera, Juan Caballeria
Medicina Clínica.2017; 149(12): 542.     CrossRef
Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
Giuseppe Della Pepa, Claudia Vetrani, Gianluca Lombardi, Lutgarda Bozzetto, Giovanni Annuzzi, Angela Rivellese
Nutrients.2017; 9(10): 1065.     CrossRef
What Is the Optimal Dietary Composition for NAFLD?
Elena S. George, Audrey C. Tierney, Katrina L. Campbell, Graeme A. Macdonald, Ingrid J. Hickman
Current Hepatology Reports.2017; 16(4): 346.     CrossRef
Non-alcoholic fatty liver disease: A poorly known pandemic
Salvador Augustin, Isabel Graupera, Juan Caballeria
Medicina Clínica (English Edition).2017; 149(12): 542.     CrossRef